You are here: Industry Insights > Lonza

News List

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate prnasia
January 29, 2022
HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, and Lonza, a global development and manufacturing partner to the pharma...
Lonza Drug Product Services Participates in RealHOPE Project contractpharma
January 19, 2022
Initiative aims to measure real-life events during drug handling that can destabilize protein-based therapeutics.
Lonza, Forbion and BioGeneration Ventures Extend Collaboration contractpharma
January 18, 2022
To add development and manufacturing services of small molecules.
Lonza signs five-year collaboration deal with VC firm Bioqube to speed up portfolio companies’ development and manufacturing CPhIonline
December 01, 2021
The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies.
Lonza, Sheba Medical Center Leverage Cocoon Platform for Cell Therapy contractpharma
August 13, 2021
Customizable, patient-scale cell therapy platform aims to streamline manufacturing to improve process efficiency and reliability.
Lonza, CN Bio Partner on Prevalidated Hepatocytes for Organ-on-a-chip Range contractpharma
July 20, 2021
Lonza will supply cells to be prequalified for use in CN Bio’s innovative PhysioMimix OOC range of Single- and Multi-Organ Microphysiological Systems.
Lonza Extends Collaboration for Monoclonal Antibody Supply at Scale americanpharmaceuticalreview
July 19, 2021
Lonza, a CDMO partner to the biopharma industry, announced the extension of its collaboration with a major biopharmaceutical partner for the commercial-scale manufacture of monoclonal antibodies, under a long-term agreement.
Lonza extends collaboration with biopharma client for antibody drug conjugate supply expresspharma
July 19, 2021
Lonza Group has extended collaboration with a major biopharma industry client for the supply of an antibody drug conjugate (ADC) against hard-to-treat cancers, the company said in a statement.
Lonza Finalizes Divestment of Specialty Ingredients Business contractpharma
July 05, 2021
The agreement with Bain Capital and Cinven was previously announced in February.
Lonza to invest in mid-scale API manufacturing expansion at Chinese facility cphi-online
June 30, 2021
The expansion of mid-scale capacity will enable the company to offer a smooth transition between early-phase and large-scale commercial production.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page